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INTRODUCTION
Allo-HSCT represents a potent therapy of malignant and non-malignant hematologic diseases (1). In the care of patients with malignant diseases it was initially developed to follow high dose chemo/radiation therapy in order to rescue from therapyrelated bone marrow failure, however the emphasis has now shifted towards allo-HSCT as a strategy to facilitate GVT activity (2). GVHD remains a major complication of allo-HSCT resulting in significant morbidity and mortality (3, 4) , and strategies to suppress GVHD are often associated with broad suppression of the immune system leading to immune deficiency and compromised anti-tumor activity (5). Molecular pathways that have been targeted in preclinical studies to accomplish separation of GVHD from GVT activity include the mammalian target of rapamycin (mTOR), histone deacytelase (HDAC), and NF-κB (via proteasome inhibition) (6). The NF-κB family member c-Rel is a transcription factor that regulates lymphocyte survival and proliferation following antigen receptor triggering and plays dominant roles in inflammation, auto and alloimmunity (7-10). c-Rel regulates expression of many inflammatory cytokines and is expressed in T and B-cells as well as monocytes/macrophages and dendritic cells (11). Immune defects secondary to c-Rel deficiency have been attributed to impaired activation of lymphocytes, in particular T-cells. In T-cells, the main target gene of c-Rel is interleukin 2 (IL-2), a cytokine required for normal T-cell proliferation and differentiation. Previous reports demonstrated that c-Rel-deficient T-cells showed reduced Th1 but normal Th2 responses (12, 13) and are compromised in the generation of anti-inflammatory natural Tregs (14-18) and pro-inflammatory Th17 cells (18, 19) . Given the limitations of existing immunosuppression-based therapies for GVHD and the pivotal roles of c-Rel in T-cell proliferation and function, we employed strategies targeting the c-Rel pathway, including
RESULTS
c-Rel Expression Is Upregulated During Allo-HSCT
We first analyzed the biological significance of c-Rel for hematopoietic reconstitution and T-cell activation after allo-HSCT. We performed studies assessing cRel expression in T-cells in the setting of radiation-induced injury as well as GVHD ( Fig.   1A and Supplementary Fig. S1 ). After irradiation and especially during GVHD, IL-2, CD25 (IL-2R ), and c-Rel were upregulated, consistent with lymphocyte activation. cRel expression was analyzed by both intracellular and intranuclear staining (22) , and the results were closely correlated ( Fig. 1B and C) . Hematopoietic stem cell functions, including the development of lymphoid and myeloid lineages, are not known to be dependent on c-Rel activity. To confirm this, we performed an allo-HSCT utilizing c-Rel -/-donor bone marrow (BM) in a MHC-disparate allo-HSCT model. c-Rel -/-BM engrafted and reconstituted recipients as efficiently as wild-type (WT) BM (Fig. 1D ). We also sought to determine if c-Rel activity in cells other than donor T-cells played a role for GVHD development by using different combinations of c-Rel -/-BM and T-cells as donor source ( Fig. 1E ) as well as utilizing c-Rel -/-mice as recipients (Fig. 1F ). c-Rel deficiency in donor BM or in the recipient did not impact on survival or GVHD scores.
ͺ amelioration of GVHD as determined by survival, weight loss, histopathology of GVHD target organs, and clinical GVHD scores (Supplementary Fig. S2 and data not shown).
Moreover, we evaluated the profiles of donor T-cells in the spleens of recipient mice on day 7 revealing that the effector/naïve (T E /T N ) ratios were decreased for both CD4 + and CD8 + T-cells, and we observed lower CD8 + T E /Tregs ratios in mice receiving c-Rel -/-Tcells compared to recipients of WT T-cells ( Fig. 2A) . We also found increased thymic cellularity on day 14 in recipients of c-Rel -/-T-cells compared to WT T-cells, indicating reduced thymic GVHD (Fig. 2B) . Furthermore, c-Rel -/-T-cells expressed significantly lower levels of the intestinal homing marker LPAM-1 on T E cells (Fig. 2C) , consistent with the findings that recipients of c-Rel -/-T-cells had much lower numbers of infiltrating donor T-cells in mesenteric lymph nodes (mLN) and small intestines (SI) ( Fig. 2D and E).
Importantly, the absolute numbers of Tregs infiltrating the SI showed no difference between recipients of WT and c-Rel -/-T-cells (Fig. 2F) , reinforcing that the net outcome of the T-cell balance is shifted towards T-cell suppression with significantly lower CD8 + T E /Tregs ratios in the SI of recipients of Rel -/-T-cells (Fig. 2E ).
Unlike in vitro (7), we found that a greater percentage of c-Rel -/-donor T-cells produced IL-2 compared to WT T-cells on day 7 after allo-HSCT, resulting in IL-2 serum concentrations above the Kd (meaning that more than 50% of IL-2 receptors will be occupied) in recipients of c-Rel -/-T-cells and in significantly lower levels in recipients of WT T-cells ( Fig. 3A and B ). STAT5 is a negative regulator of IL-2 production (23, 24).
When we analyzed STAT5 phosphorylation (pSTAT5) in c-Rel -/-and WT T-cells we found that splenic c-Rel -/-T-cells harvested 96 hours after allo-HSCT exhibited impaired IL-2-mediated induction of pSTAT5 (Fig. 3C ). This lower responsiveness to IL-2 is consistent with decreased expression of CD25 by c-Rel -/-T E cells (data not shown) and ͻ suggests decreased negative feedback on IL-2 production resulting in a relative increase in IL-2 secretion compared to WT T-cells. Furthermore, consistent with a previous report (10), we observed a dramatic increase in the numbers of donor-derived Tregs in recipients of c-Rel -/-T-cells starting after day 7 post HSCT ( Fig. 3D ), whereas host Tregs were hardly detectable. Expression of CD25 on those Tregs was higher than that of WT Tregs (Fig. 3E ). These data suggest that competition for IL-2 between T E and Tregs results in promotion of alloactivation in recipients of WT T-cells, and in expansion of
Tregs in recipients of c-Rel-deficient T-cells (Fig. 3F ). Neuropilin-1 (Nrp-1) was recently identified as a marker for natural Tregs (25, 26) . As expected, the vast majority of c-Reldeficient Tregs in our experiments were Nrp-1 -induced Tregs (data not shown). To further investigate the potential role of Tregs in the amelioration of GVHD, we performed in vivo depletion of Tregs using FoxP3-DTR transgenic mice that express the diphtheria toxin receptor (DTR) under control of the FoxP3 promoter (27) as donor T-cell source.
Elimination of Tregs in vivo by DT administration on day 13 worsened the survival of recipients of c-Rel-deficient T-cells (c-Rel deficiency was achieved by pre-treatment of donor T-cells with a small molecule inhibitor compound, see below for more details), suggesting that donor Tregs indeed contributed to the amelioration of GVHD ( Fig. 3G and Supplementary Fig. S3 ). Depletion of donor Tregs in recipients of T-cells with normal c-Rel activity did not affect GVHD severity, indicating that in contrast to animals receiving c-Rel-deficient T-cells, the Treg numbers in animals receiving WT T-cells was too low during early GVHD to be biologically significant. Importantly, Tregs from c-Rel -/-mice are functional (28, 29) and could reduce GVHD in our model (Fig. 3H ).
Research. 
ͳͲ
T-cells Treated With a Small Molecule c-Rel Inhibitor Compound Cause Less
GVHD
Some natural compounds and their synthetic derivatives inhibit Rel or NF-κB via specific interaction with the Cysteine residues critical for binding to the specific κB-DNA sequence (20). For example, dehydroxymethylepoxyquinomicin (DHMEQ) was shown to inhibit NF-κB binding activity, however, the complex structures and poor pharmacokinetics due to reactive sites found in natural products made them unsuitable for further development. To develop direct Rel inhibitors, we established an assay (fluorescence polarization (FP) assay; for more details, see METHODS) for high throughput screening. Screening of a library of 15,000 compounds yielded 20 hits. We conducted structure activity relationship (SAR) studies of these initial hits using EMSA and finally identified the hydrophobic small molecule Pyrimidinetrione and its derivatives as potent and highly specific inhibitors of c-Rel activity, having a 20í200 fold higher inhibitory effect on c-Rel and NF-κB than on other transcription factors such as Oct1 and AP1 ( ͳͳ treated with empty vehicle (DMSO) (Fig. 4F) and even though the inhibitory effect of the compound was temporary and c-Rel activity returned to normal by day 4 after allo-HSCT (data not shown), those T-cells caused significantly reduced GVHD (Fig. 4G ). We also observed higher IL-2 secretion from donor CD4 + T-cells on day 4 in this experiment ( Supplementary Fig. S4 ). Of note, we recently developed a DMSO-free lipid-based formulation of IT-603 using the FDA-approved non-ionic surfactant cremophor.
Intraperitoneal injection of this formulation was well tolerated and allowed us to study pharmacokinetics (Table 1 and Fig. 4H ), in a first step toward development of a c-Rel inhibitor drug.
Treatment of T-cells With a c-Rel Inhibitor Compound Does Not Compromise Antitumor Activity
A recent study found evidence indicating that in recipients of c-Rel -/-T-cells GVT activity against A20-TGL mouse lymphoma cells can be intact (10). We confirmed these findings and were, moreover, able to demonstrate that this effect can be sustained with T cell doses as low as 25% of the standard dose (data not shown), and when targeting less immunogenic A20 tumor cells as well as a solid tumor RENCA (renal cell carcinoma, data not shown).
In addition, c-Rel -/-T-cells displayed strong anti-tumor activity against EL4-TGL Tcell lymphoma cells even in the absence of T-cell alloactivation (Fig. 5A) . In this syngeneic model, the level of CD25 on c-Rel -/-CD8 + T-cells on day 7 after transplantation was similar to that of WT T-cells (Fig. 5B ), in striking contrast to the allo-HSCT setting, where CD25 levels in c-Rel -/-T-cells were significantly decreased (Fig.   5C ). We performed a similar experiment using B16-TGL melanoma tumor cells and Importantly, WT T-cells pre-treated with a c-Rel antagonist mediated GVT activity in several tumor models ( Fig. 5D and GΫI), indicating that viable and functional T-cells are present. It is therefore highly likely that the diminished capacity of these T-cells to induce GVHD is due to the c-Rel inhibitory mechanism of the small molecule compound and not simply due to a non-specific effect of the in vitro manipulation procedure.
However, we did observe that GVT activity of WT T-cells treated with inhibitor compound was slightly less than the GVT activity of c-Rel -/-T-cells, and we found moderate reduction in antigen-specific T-cell activation (but not alloactivation) in vitro in the presence of vehicle alone ( Supplementary Fig. S5 ). As a result of our ongoing efforts to establish less toxic compound formulations we recently succeeded in developing a regimen for systemic administration of the inhibitor compound as GVHD therapy, and we were able to establish in vivo efficacy ( ͳͷ setting of GVHD, pSTAT5 in c-Rel deficient donor T-cells is decreased, which over time leads to increased IL-2 levels (due to decreased negative feedback), and renders T E at the same time non-competitive (due to decreased CD25 expression), while allowing Tregs, a T-cell population that expresses CD25 by definition, to outcompete T E . Our findings as well as a recently described similar concept of competition for IL-2 between T E and Tregs (23, 24) indicate that this mechanism may indeed have significant implications for alloactivation and GVHD, and it will be an important line of future research to evaluate the kinetics of T E and Tregs in response to interventions modulating the IL-2 pathway (33). Reported roles of c-Rel in T-cell responses and transplantation immunology in comparison with our findings during GVHD are summarized in Table 2 . However, since c-Rel activity is restricted to a small number of hematopoietic lineages, a c-Rel-specific inhibitor will likely have a better safety profile than a pan-NF-κB inhibitor.
Indeed, we have evidence that systemic administration of the c-Rel inhibitor compound discovered by us is feasible, safe, and effective. Furthermore, Rel/NF-κB factors are also 
resistance, and metastasis of lymphoid malignancies, breast, head, and neck cancers (9, 40). We found in a preliminary experiment that intraperitoneal c-Rel inhibitor compound administration displayed antineoplastic activity in a xenograft model of human diffuse large B-cell lymphoma (data not shown).
In conclusion, our data provide for the first time evidence for a differential role of c-Rel for alloactivation versus antigen-specific T-cell activation: while c-Rel activity is critically important for T-cell activation during GVHD, it is dispensable for antigen-specific TCR activation. As a result, inhibition of c-Rel activity reduces the severity of GVHD without compromising anti-tumor activity of T-cells. Our findings validate c-Rel as a highly promising therapeutic target, and we demonstrate biological benefits of inhibition of c-Rel activity in both mouse and human T-cells with a highly specific small molecule compound. Drug development studies are currently underway in an effort to translate this technology from bench to bedside.
METHODS
Mice and Bone Marrow Transplantation
We obtained female C57BL/6 (B6, (42) ͳͻ free CD28RE versus bound CD28-Rel complex was used to screen for compounds that disrupted CD28-Rel interaction.
Assessment of GVHD and GVT; in vivo BLI and cell lines
Mice were monitored daily for survival and weekly for GVHD clinical scores (44).
Small intestine, large intestine, liver, and skin samples were evaluated histologically for evidence of GVHD and scored as previously described (45). In GVT experiments, we determined the bioluminescent signal intensity (BLI) of tumor bearing mice twice weekly as described previously (46). We superimposed pseudocolor images showing the wholebody distribution of bioluminescent signal intensity on grayscale photographs and determined total flux (photons s -1 ) for individual mice. We determined the cause of death (tumor versus GVHD) by necropsy and histopathology as previously described (45 
Serum Cytokines Analyses
Blood was collected into microcentrifuge tubes, allowed to clot and centrifuged, (24). Briefly, mice were sacrificed instantaneously and splenocytes were exposed to different concentrations of mouse IL-2 for 10 minutes at 37 , followed by fixation with 1.6% PFA, and permeabilization with 90% methanol. During this process, membrane-bound IL-2 was stripped from cell surface by a 2-minute incubation with 0.1 M Glycine buffer equilibrated at pH 4.0, followed by a 5-minute wash in RPMI before the exposure to exogenous IL-2. All flow cytometry was performed on an LSR II (BD Biosciences) and analyzed with FlowJo 
Human T-cell Cytotoxicity and Limited Dilution Assays
In vitro cytotoxicity analyses of human CMV-specific T cells as well as human Wilms tumor 1 (WT1) and human Epstein-Barr Virus (EBV) specific T cells were performed as previously described (30). In brief, CMV specific T cells were generated from PBMC of a healthy donor by repeated in vitro stimulations with an autologous EBV 
Statistics
Data are presented as mean ± SEM. Survival data were analyzed with the MantelCox log-rank test. For nonsurvival pointwise analyses, unpaired t test was used for comparisons between two experimental groups, or nonparametric Mann-Whitney U test was used for non-Gaussian distributions, and ANOVA was used for comparisons of more than two groups. All statistical analyses were performed using GraphPad Prism 5 (La 
Research. , #13  decreased  Th2  normal  #12, #13  increased  Th17  defective  #12, #19  no change  nTreg  defective  #14, #15, #16, #17  increased  iTreg  defective  #17  increased  Graft survival 
ʹ
prolonged #31, #32 N/A GVHD survival prolonged (donor T-cells) #10 prolonged IL-2 defective (in vitro) #7, #8 increased T E /T N ratio decreased (in vitro) #7, #8 decreased T-cell activation defective (in vitro) #7, #8 decreased T-cell proliferation defective (in vitro) #7, #8
